

## Part II

### Summary of Product Characteristics

#### 1 NAME OF THE MEDICINAL PRODUCT

Anthranol 1.0%

#### 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Dithranol 1.0% w/w.

For excipients, see section 6.1.

#### 3 PHARMACEUTICAL FORM

Ointment

A waxy yellow ointment.

#### 4 CLINICAL PARTICULARS

##### 4.1 Therapeutic Indications

Anthranol 1.0 Ointment is indicated for the topical treatment of psoriasis.

##### 4.2 Posology and method of administration

Anthranol 1.0 Ointment is one of a range of dithranol products, which include 0.4 and 2.0 ointments.

Treatment should begin with Anthranol 0.4. Clinical response and tolerance will determine the necessity for progression to Anthranol 1.0 and subsequently Anthranol 2.0.

Apply the ointment once daily, sparingly to the psoriatic plaque. Surrounding normal skin should be protected with white soft paraffin. Leave the ointment on for the required time then remove excess ointment with a paper tissue and wash off the remainder thoroughly.

If Anthranol has been applied to the scalp, the ointment should be removed by shampooing.

The initial daily treatment time with each strength should not exceed 10 minutes. The time may be increased gradually over a period of 7 days to a maximum of 30 minutes. The daily treatment time should not normally exceed 30 minutes. In the event of undue irritation, stop treatment for 2 days and resume on alternate days.

Treatment should be continued at the optimum tolerated strength and leave-on time, depending on patient response.

##### 4.3 Contraindications

Anthranol 1.0 Ointment is contra-indicated in pustular psoriasis and is not suitable for the treatment of acute psoriasis. It should not be used by patients with known hypersensitivity to the ingredients.

Anthranol 1.0 Ointment should not be applied to the face, the inside of the thighs, the genital region or skinfold areas.

#### **4.4 Special warnings and precautions for use**

Dithranol is a strong irritant, the hands should always be washed after use and the product kept away from the eyes. Should contact with the eyes occur, bathe immediately with water and seek medical advice.

The product will cause staining and discolouration of the skin. It will also stain or discolour clothing and may stain bathroom ware. Stains on clothing should be assumed to be permanent; stains on bathroom ware may be removed by bleach.

#### **4.5 Interaction with other medicinal products and other forms of interaction**

None.

#### **4.6 Pregnancy and lactation**

Although there is no evidence to support the safety of Anthranol in pregnancy and lactation, no adverse effects have been reported.

#### **4.7 Effects on ability to drive and use machines**

None.

#### **4.8 Undesirable effects**

Dithranol preparations can cause irritation; if this develops, or redness is observed on adjacent normal skin, the frequency of application should be reduced.

#### **4.9 Overdose**

Not applicable.

### **5 PHARMACOLOGICAL PROPERTIES**

#### **5.1 Pharmacodynamic properties**

The use of dithranol in the treatment of psoriasis is well established. It has been suggested that the mode of action involves combination with deoxyribonucleic acid and other nucleic acids, inhibiting the synthesis of nucleic protein and thus decreasing the cellular proliferation, which is increased in the psoriatic epidermis.

#### **5.2 Pharmacokinetic properties**

The product is a topical preparation, which acts locally at the site of application. Pharmacokinetic data are not applicable.

#### **5.3 Preclinical safety data**

Not applicable. Dithranol has been in wide-spread use for many years. The relevant information is given in section 4 of the Summary of Product Characteristics.

## **6 PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

White soft paraffin  
Cetyl alcohol  
Sodium laurilsulfate  
Salicylic acid  
Light liquid paraffin

### **6.2 Incompatibilities**

Not applicable.

### **6.3 Shelf Life**

3 years.

### **6.4 Special precautions for storage**

Do not store above 25°C.

### **6.5 Nature and contents of container**

Internally lacquered aluminium tubes of 50g.

### **6.6 Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product**

No special requirements.

## **7 MARKETING AUTHORISATION HOLDER**

Stiefel Laboratories (UK) Ltd.  
Holtspur Lane  
Wooburn Green  
High Wycombe  
Buckinghamshire  
HP10 0AU  
England

## **8 MARKETING AUTHORISATION NUMBER**

PA 144/17/1

## **9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 23 March 1990

Date of last renewal: 23 March 2005

## 10 DATE OF REVISION OF THE TEXT

June 2006